Health ❯ Healthcare ❯ Chronic Diseases

Type 2 Diabetes

Management Strategies Treatment Options Management and Treatment Cardiovascular Risk Weight Management Medication Effects Obesity Associated Conditions Insulin Sensitivity Management

Wave Life Sciences Shares Plunge 30% After Early Obesity Trial Readout

The readout showed a 14% placebo-adjusted drop in visceral fat with a clean safety profile in a lighter cohort.

Study Finds Metformin Lowers Blood Sugar by Acting on a Brain Circuit

Heart Risks Rebound After GLP-1 Breaks, New Data Show Continuous Use Is Safest

GLP-1 Drugs Tied to Lower Addiction Risk and Harms in Large VA Study

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

Pfizer to Commercialize Sciwind’s GLP-1 Ecnoglutide in China Under Exclusive License

Major Lancet Analysis Finds Most Statin Label Side Effects Not Caused by the Drugs

Oral Semaglutide Cuts Serious Heart-Failure Events 22% in Type 2 Diabetes With Heart Failure

Meta-Analysis Finds GLP-1 Drugs Show Little Short-Term Impact on Obesity-Linked Cancer Risk

Real-World Study Finds Semaglutide and Tirzepatide Cut Cardiovascular Risk in Type 2 Diabetes

Metformin Blunts Exercise Benefits in Rutgers Randomized Trial

India Clears Ozempic for Type 2 Diabetes as Novo Nordisk Prepares Launch

EMA Approves Cardiovascular Indication for Novo Nordisk’s Rybelsus

17 Million U.S. Youth Eligible for GLP-1 Therapies Face Coverage and Care Barriers

Mounjaro Rivals Trulicity in Cardiovascular Safety and Lowers All-Cause Mortality

Glipizide Linked to 13% Higher Cardiovascular Risk Than DPP-4 Inhibitors

GLP-1 Agonists Cut Dementia and Mortality Risk Versus Metformin in Type 2 Diabetes

Researchers Identify Brainstem Nerve Cells Driving Semaglutide’s Weight-Loss Effects

Type 2 Diabetes Drug Shows Potential to Lower Dementia Risk by 35%

Eli Lilly's Tirzepatide Shows 94% Reduction in Diabetes Risk